Korean J Hepatol.  2010 Dec;16(4):389-396. 10.3350/kjhep.2010.16.4.389.

Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma

Affiliations
  • 1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. pindra@empal.com
  • 2Department of Internal Medicine and Healthcare Research Institute, Seoul National University Hospital, Healthcare System Gangnam Center, Seoul, Korea.
  • 3Department of Internal Medicine, Seoul National University College of Medicine, Seoul Municipal Boramae Hospital, Seoul, Korea.
  • 4Department Pathology, Seoul National University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND/AIMS
P2/MS is known as a simple, accurate, and noninvasive marker for determination of the degree of hepatic fibrosis in patients with viral hepatitis. We aimed to validate P2/MS in patients with HCC.
METHODS
Consecutive HCC patients who underwent surgical resection between June 2007 and March 2009 at Seoul National University Hospital were enrolled. Fibrosis stage was reviewed and assessed according to METAVIR scoring. P2/MS values [platelet count (109/L)]2/[monocyte fraction (%)xsegmented neutrophil fraction (%)] and other noninvasive fibrosis scoring systems were calculated.
RESULTS
A total of 171 patients were included; seven patients with METAVIR F1, 31 with F2, 41 with F3, and 92 with F4. The area under the receiver-operating characteristic curve of P2/MS was 0.804 [95% confidence interval (CI), 0.681~0.927] for detection of significant fibrosis (F2-F4) and 0.769 (95% CI, 0.698~0.839) for detection of histological cirrhosis (F4). At a value < 62, P2/MS detected significant fibrosis with a specificity of 85.7% (95% CI, 42.0~99.2) and a positive likelihood ratio of 4.268 (95% CI, 0.692~26.309); and at a value > 115, P2/MS ruled out significant fibrosis with a sensitivity of 90.2% (95% CI, 84.4~94.1) and a negative likelihood ratio of 0.34 (95% CI, 0.106~0.095). P2/MS had a superior efficacy for detection of hepatic fibrosis in patients with HCC compared to the other noninvasive panels.
CONCLUSIONS
P2/MS can accurately detect fibrosis in patients with HCC. Thus, P2/MS might be utilized as a noninvasive index reflecting the degree of hepatic fibrosis in HCC patients.

Keyword

P2/MS; Fibrosis; Hepatocellular carcinoma

MeSH Terms

Aged
Area Under Curve
Carcinoma, Hepatocellular/complications/*diagnosis/pathology
Cohort Studies
Female
Health Status Indicators
Humans
Liver Cirrhosis/complications/*diagnosis/pathology
Liver Neoplasms/complications/*diagnosis/pathology
Male
Middle Aged
Monocytes/cytology
Neoplasm Staging
Neutrophils/cytology
Platelet Count
ROC Curve
Reproducibility of Results
Retrospective Studies
Severity of Illness Index
Full Text Links
  • KJHEP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr